Pure Global: Brazil's 3D-Printed MedTech Scramble - Inside ANVISA's Surprise Rule Shake-up.

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

Pure Global: Brazil's 3D-Printed MedTech Scramble - Inside ANVISA's Surprise Rule Shake-up.

Ascolta gratuitamente

Vedi i dettagli del titolo

3 mesi a soli 0,99 €/mese

Dopo 3 mesi, 9,99 €/mese. Si applicano termini e condizioni.

A proposito di questo titolo

Brazil's regulatory agency, ANVISA, has just released a surprise draft guidance for personalized, 3D-printed medical devices, sending shockwaves through the MedTech industry. With a very short 30-day window for public feedback, international companies are now scrambling to understand the complex new rules for software validation and data privacy that could disrupt their market access strategies. This episode dives deep into the specific challenges and hidden opportunities within this proposal. We analyze the potential requirement for Brazil-specific software validation, which may conflict with existing FDA or CE Mark approvals. We also unpack the ambiguous data localization clauses that could threaten the global operational models of many manufacturers. **Case Study Spotlight:** Imagine your company has perfected a workflow for creating patient-specific implants in a central European facility. You're on the verge of expanding into Brazil, but ANVISA's new rules could suddenly make your data transfer processes non-compliant, forcing a multi-million dollar investment in local infrastructure. Is your current regulatory strategy agile enough to handle this? **Key Questions Answered:** * Is ANVISA's 30-day feedback window a genuine consultation or a new barrier to entry? * What are the specific cybersecurity and data privacy risks hidden in the new draft? * How can you effectively challenge a proposed regulation that conflicts with your global model? * What are the unwritten rules for submitting feedback to ANVISA that actually gets considered? * Could Brazil's new framework for personalized devices set a new, complex standard for all of LATAM? Pure Global offers end-to-end regulatory consulting to help MedTech innovators navigate precisely these kinds of challenges. We combine local, in-country expertise with advanced AI tools to streamline global market access and ensure you're always ahead of regulatory changes. Don't let surprise regulations derail your expansion. Contact us at info@pureglobal.com or visit us at https://pureglobal.com/.

Ancora nessuna recensione